7 March 2023
Kanabo Group plc
("Kanabo", the "Group" or the "Company")
Appointment of Auditor
Kanabo Group plc (LSE: KNB), a leading patient-focused healthtech ecosystem and provider of personalised medicinal treatments, is pleased to announce the appointment of MHA MacIntyre Hudson ("MHA") as the Company's auditors with immediate effect. The appointment of MHA is subject to approval by the shareholders at the next Annual General Meeting of the Company.
Further to the announcement made on 2 December 2022, Jeffreys Henry LLP, the Company's previous auditors, confirmed there are no circumstances connected with its resignation which it considers should be brought to the attention of members or creditors of the Company.
Enquiries:
| Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial Officer
| via Vigo Consulting +44 (0)20 7390 0230 |
| Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker/ Lucy Williams / Charles Goodfellow
| +44 (0)20 7469 0930 |
| Vigo Consulting (Financial Public Relations/Investor Relations) Jeremy Garcia / Fiona Hetherington / Verity Snow kanabo@vigoconsulting.com | +44 (0)20 7390 0230
|
About Kanabo Group Plc
Founded in 2017, Kanabo Group Plc (LSE:KNB) is a patient-first HealthTech ecosystem, focused on delivering high quality and innovative medical treatments, via its leading-edge technology platform and disruptive product offering.
The Company is a world leader in the research, development and commercialization of regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Patient care is delivered via the company's NHS-approved online telehealth platform offering video consultations, online prescriptions and access to primary care services. In January 2023, the Company successfully combined its technological and product expertise to launch the Beta phase of its medical cannabis business, initially for chronic pain management, under the new Treat-It brand.
Kanabo Group is committed to evolving more accessible healthcare experiences for every patient.
Visit www.kanabogroup.com for more info.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.